CDC20 promotes prostate cancer progression via modulating c-MYC and PI3K-AKT signaling Authors: Jixiang Ding, Xinyu Xu, Ningning Zhang, Jiaojiao Chen, Wenhui Zhu, Ke Lu, Chaozhong Wang, Zhenyu Fu, Jing Zhai, Yizhou Wang Published: 2026 ABSTRACT SummaryProstate cancer shows substantial variability in clinical outcomes, underscoring the need for reliable biomarkers and mechanistic insights. Analysis of The Cancer Genome Atlas data identified CDC20 as an independent prognostic factor with elevated expression in prostate cancer. Functional studies in DU145 and PC-3 cells demonstrated that CDC20 promotes cell proliferation, migration, invasion, and cell cycle progression. Co-immunoprecipitation and loss-of-function analyses indicated that CDC20 interacts with c-MYC and influences PI3K-AKT signaling. In a xenograft model, CDC20 knockdown reduced tumor growth, whereas its overexpression enhanced tumor progression. These findings suggest that CDC20 contributes to prostate cancer progression, at least in part, through a c-MYC-associated PI3K-AKT signaling axis, and support its potential relevance for prognostic assessment and therapeutic targeting.Subject areas: Health sciences, Medicine, Medical specialty, Internal medicine, Oncology Introduction Prostate cancer (PCa) is the second most frequently diagnosed malignancy and the fifth leading cause of cancer-related mortality among men worldwide.1,2 Although early-stage PCa can often be effectively managed with surgery, endocrine therapy, and other interventions, a substantial proportion of patients eventually progress to castration-resistant prostate cancer (CRPC), which is associated with limited therapeutic options and poor survival outcomes.3,4 Therefore, identifying robust prognostic biomarkers and elucidating the molecular mechanisms driving PCa progression remain major clinical and research challenges.5,6 Tumor development and progression are driven by dysregulated gene expression and aberrant signaling pathways.7 Advances in high-throughput sequencing and public databases, such as The Cancer Genome Atlas (TCGA), have facilitated systematic identification of genes associated with tumor progression and patient prognosis.8,9 However, many reported prognostic markers lack sufficient specificity or mechanistic clarity, limiting their translational value in clinical practice.10 Consequently, uncovering prognostic genes with well-defined biological functions is critical for improving risk stratification and developing targeted therapeutic strategies in PCa. Cell division cycle 20 (CDC20) is a key regulator of cell cycle progression that functions as an essential activator of the anaphase-promoting complex/cyclosome (APC/C), thereby controlling the G2/M transition through the degradation of cell-cycle-related substrates.11,12 Aberrant overexpression of CDC20 has been reported in multiple malignancies, including colorectal, breast, and liver cancers, where it is associated with enhanced tumor proliferation, invasion, and unfavorable prognosis.13,14,15 Importantly, emerging studies have also investigated CDC20 in PCa, demonstrating that CDC20 is frequently upregulated in PCa tissues and is associated with tumor progression, metastasis, drug resistance, and poor clinical outcomes.15,16,17 Functional studies have further suggested that CDC20 promotes proliferation and cell cycle progression in PCa cells, highlighting its potential oncogenic role in this disease.18,19,20 However, despite these findings, the detailed molecular mechanisms by which CDC20 contributes to PCa progression, particularly in relation to key oncogenic signaling pathways, remain incompletely understood. The phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway plays a central role in regulating tumor cell survival, proliferation, and metabolism.21 In PCa, this pathway is frequently dysregulated, often as a result of PTEN loss or abnormal AKT activation, and contributes to disease progression and therapeutic resistance.22 c-MYC, a critical oncogenic transcription factor, is an important downstream effector of PI3K-AKT signaling and promotes malignant transformation by regulating genes involved in cell growth and metabolism.23 Emerging evidence suggests that CDC20 may influence tumor progression by modulating c-MYC protein regulation in a post-transcriptional manner.24 However, whether such a regulatory relationship exists in PCa and how it relates to PI3K-AKT signaling remain unclear. In this study, we integrated TCGA-based bioinformatics analyses with in vitro and in vivo experiments to identify key prognostic genes in PCa and to investigate their biological functions and underlying molecular mechanisms. Compared with previous studies, our work not only systematically evaluates the prognostic significance of CDC20 using large-scale clinical datasets but also provides experimental evidence linking CDC20 to the c-MYC/PI3K-AKT signaling axis in PCa. We focused on CDC20 to evaluate its role in PCa cell proliferation, migration, invasion, and cell cycle regulation and to explore its association with c-MYC and PI3K-AKT signaling. These findings extend current knowledge by offering mechanistic insights into CDC20-mediated tumor progression and highlight its potential as both a prognostic biomarker and a therapeutic target in PCa. Results Screening of DEGs and pathway enrichment analysis in TCGA-PRAD Transcriptomic data of PCa were obtained from the TCGA-PRAD cohort. Differentially expressed genes (DEGs) between tumor and normal prostate tissues were identified using the limma package, resulting in a total of 248 DEGs. The heatmap in Figure 1A illustrates distinct expression patterns, with red and blue colors indicating relatively high and low expression levels, respectively. Screening of DEGs and pathway enrichment analysis in TCGA-PRAD (A) Heatmap of DEG expression in normal and tumor tissues. Red indicates high gene expression, and blue indicates low gene expression. (B) Bubble plot of GO enrichment analysis for DEGs, showing enrichment in biological process (BP), cellular component (CC), and molecular function (MF), where the size of bubbles represents the number of enriched genes and the color represents the enrichment significance. (C) Bubble plot of KEGG pathway enrichment analysis for DEGs. The size of bubbles represents the number of enriched genes and the color represents the enrichment significance. To explore the biological significance of these DEGs, Gene Ontology (GO) enrichment analysis was performed using the clusterProfiler package. The DEGs were primarily enriched in biological processes related to regulation of inflammatory response, immunoglobulin complex, and cytokine activity across the categories of biological process (BP), cellular component (CC), and molecular function (MF) (Figure 1B). Consistently, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed significant enrichment in pathways including cytokine-cytokine receptor interaction, MAPK signaling, and PI3K-AKT signaling (Figure 1C), suggesting that these DEGs may participate in tumor progression and immune regulation in PCa. Identification of prognostic genes and construction of a risk model To identify DEGs associated with patient prognosis, univariate Cox proportional hazards regression analysis was performed. Among the 248 DEGs, 36 genes were significantly correlated with disease-free survival (DFS), of which 12 were associated with increased risk of disease progression or recurrence (HR [hazard ratio] > 1) and 24 were protective (HR < 1), as illustrated in the forest plot (Figure 2A). Kaplan-Meier survival analysis confirmed that high expression of representative risk genes was associated with significantly poorer DFS compared with low-expression groups (Figure 2B). Notably, DFS events in the TCGA-PRAD (prostate adenocarcinoma) cohort primarily reflect biochemical recurrence or disease progression rather than death events, which may account for the observed number of events in the survival curves. Screening of prognostic genes in the TCGA-PRAD cohort via univariate Cox regression analysis (A) Forest plot of univariate Cox regression analysis, showing 36 significantly prognostic genes screened from 248 DEGs, where each dot represents the HR of a gene and the horizontal line represents the 95% confidence interval; HR > 1 indicates that high expression is associated with increased survival risk, and HR < 1 indicates a protective effect. (B) Kaplan-Meier survival curves of representative genes. The difference in survival probability between the high-expression group (red) and low-expression group (blue) was verified by log rank test, confirming their prognostic value. Subsequently, multivariate Cox regression analysis was performed adjusting for clinical variables including age and pathological stage, identifying 8 genes independently associated with DFS (Figure 3A). Based on these genes, a risk model was constructed, and a risk score was calculated for each patient. Patients were stratified into high- and low-risk groups according to the median risk score. Kaplan-Meier analysis revealed that patients in the high-risk group had significantly poorer DFS than those in the low-risk group (p < 0.001; Figure 3B). Univariate and multivariate Cox regression analyses confirmed that the risk score remained an independent prognostic factor after adjustment for clinical variables, including pathological stage and Gleason score (p < 0.001; Figures 3C and 3D). Verification of Riskscore as an independent prognostic factor for PCa (A) Table comparing results of univariate and multivariate Cox regression analyses, showing the HR, 95% CI, and p value of Riskscore and other clinical variables (age, stage); in the multivariate analysis, Riskscore had an HR of 2.15, indicating it is independent of other clinical variables. (B) Kaplan-Meier survival curve. The 5-year survival rates of the high-risk group (red) and low-risk group (blue) were 42% and 78%, respectively (p < 0.001). (C and D) Forest plots of univariate (C) and multivariate (D) Cox regression analyses showing the hazard ratios (HRs), 95% confidence intervals (CIs), and corresponding p values for Riskscore and clinical variables. Riskscore remained a significant independent prognostic factor in both analyses, with HRs greater than 1 and 95% CIs that did not cross 1. (E) Pathways significantly enriched in the high-risk group. (F) Pathways significantly enriched in the low-risk group; NES represents normalized enrichment score, and the bar markers indicate the contribution of gene ranking positions to the enrichment score. To explore the biological characteristics associated with the risk model, Gene Set Enrichment Analysis (GSEA) was performed comparing high- and low-risk groups. The high-risk group was significantly enriched in pathways such as complement and coagulation cascades, extracellular matrix (ECM)-receptor interaction, and PPAR signaling, whereas the low-risk group showed enrichment in pathways related to cell cycle, DNA replication, and T cell receptor signaling (Figures 3E and 3F). Immune cell infiltration was estimated using the CIBERSORT algorithm. Significant differences in immune cell composition were observed between high- and low-risk groups. Specifically, the high-risk group had relatively higher levels of M1 macrophages and CD8+ T cells, whereas the low-risk group exhibited increased memory B cells and plasma cells. The M1/M2 macrophage ratio was elevated in the high-risk group, highlighting heterogeneity in immune microenvironment associated with the risk score (Figure S1). Identification of CDC20 as a key prognostic gene Among the 8 genes in the risk model, CDC20 exhibited a high regression coefficient (coef = 0.776; HR ≈ 2.17, Figure 4A), indicating a strong association with increased mortality risk. Analysis of TCGA-PRAD data showed that CDC20 expression was significantly higher in PCa tissues than in normal tissues (Figure 4B), and paired sample analysis confirmed marked upregulation in tumor versus matched adjacent normal tissues (Figure 4C). To further confirm the expression pattern of CDC20 in PCa patients, we explored the online data from GEO datasets, GSE35988 and GSE21032. The results also show that CDC20 upregulates in PCa tissues (Figures 4D and 4E) and has a positive correlation with Gleason score (Figure 4F) and poor disease outcome (Figure 4G). To investigate the functional role of CDC20 in PCa, its expression was first examined in PCa cell lines (DU145 and PC-3) and the normal prostate epithelial cell line RWPE-1. Western blot analysis demonstrated that CDC20 protein levels were markedly higher in DU145 and PC-3 cells than in RWPE-1 cells (Figure 4H). Finally, we examined CDC20 expression by immunohistochemistry (IHC) in PCa tissues and matched nontumor tissues. As shown in Figure 4I, PCa tissues showed much higher CDC20 expression in compared with benign prostatic epithelia. These findings suggest that CDC20 is a tumor-associated gene with potential prognostic significance in PCa. Screening of CDC20 as an independent prognostic gene for PCa and verification of its expression (A) Forest plot of multivariate Cox regression analysis, showing the regression coefficient and 95% confidence intervals of 8 independent prognostic genes; CDC20 had the highest coefficient value, suggesting it is the strongest risk factor. (B) Differential expression of CDC20 in TCGA-PRAD. Boxplot showing that CDC20 expression in cancer tissues is significantly higher than that in normal tissues. (C) Paired sample scatterplot further verifying the expression difference of CDC20 between cancer and normal tissues from the same patient. (D and E) CDC20 mRNA level was upregulated in primary and metastatic prostate cancer in datasets GSE21032 (D) and GSE35988 (E). (F) Correlation between CDC20 expression and Gleason score. (G) Kaplan-Meier survival curves for prostate cancer patients stratified by CDC20 expression. (H) Western blot detecting CDC20 protein expression in different cell lines. (I) Representative immunohistochemistry of CDC20 on benign prostatic epithelia (benign) and prostate cancer tissues (scale bars, 100 μm). CDC20 promotes proliferation and cell cycle progression of prostate cancer cells in vitro and in vivo To further explore the role of CDC20 in PCa, classical PCa cells DU145 and PC-3 cells were selected for subsequent functional assays. CDC20 expression was efficiently silenced or overexpressed in both cell lines, and successful manipulation was confirmed by western blot analysis (Figure 5A). In vitro verification of CDC20 regulating the proliferation of PCa cells (A) Verification of efficiency of overexpression or siRNA knockdown. (B) Cell proliferation curves of DU145 and PC3 cells treated with control (Ctrl), si-CDC20, and OE-CDC20. (C) Colony formation assay evaluating the effect of CDC20 on PCa cell proliferation. (D) Cell cycle distribution analysis in DU145 cells following CDC20 knockdown or overexpression. (E) In vivo tumor growth assay. ∗∗Data are presented as mean ± SD from three independent experiments (n = 3). Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. The effects of CDC20 on cell proliferation were evaluated first. CCK-8 assays showed that CDC20 knockdown significantly suppressed the proliferative capacity of DU145 and PC-3 cells, whereas CDC20 overexpression markedly enhanced cell proliferation (Figure 5B). Consistently, colony formation assays demonstrated that silencing CDC20 resulted in a substantial reduction in colony numbers, while enforced CDC20 expression significantly increased colony formation ability (Figure 5C). Given the prominent role of CDC20 in regulating cell proliferation, its impact on cell cycle progression was further examined. Flow cytometric analysis revealed that CDC20 knockdown led to significant accumulation of DU145 cells in the G2/M phase, indicating cell-cycle arrest, whereas CDC20 overexpression promoted cell cycle progression (Figure 5D). To further validate the pro-proliferative role of CDC20 in vivo, subcutaneous xenograft experiments were performed using DU145 cells with stable CDC20 knockdown or overexpression. As shown in Figure 5E, tumors derived from CDC20-silenced cells exhibited significantly reduced tumor volume and tumor weight compared with the corresponding control group. In contrast, CDC20 overexpression markedly promoted tumor growth in nude mice, as reflected by increased tumor volume and tumor weight. Collectively, these in vitro and in vivo findings demonstrate that CDC20 promotes PCa growth by enhancing cell proliferation and cell cycle progression. CDC20 enhances migration of prostate cancer cells Then we explored the role of CDC20 in PCa cell migration in vitro. Transwell invasion assays showed that silencing CDC20 significantly reduced the migrative capacity of DU145 and PC-3 cells, whereas CDC20 overexpression markedly increased cell migration (Figures 6A and 6B). In addition, wound healing assays further confirmed the regulatory effect of CDC20 on horizontal cell migration. CDC20 knockdown markedly delayed wound closure in both DU145 and PC-3 cells, whereas enforced CDC20 expression significantly accelerated wound healing rates (Figure 6C). These results indicate that CDC20 promotes the migratory and invasive capacities of PCa cells in vitro, suggesting a potential role in PCa progression. CDC20 regulates the migration of PCa cells (A) Migration of DU145 and PC3 cells after treatment with si-NC and si-CDC20 (scale bars, 50 μm). (B) Migration of DU145 and PC3 cells after CDC20 overexpression (scale bars, 50 μm). (C) Wound healing assay at 0 h, 24 h, and 48 h. ∗∗Data are presented as mean ± SD from three independent experiments (n = 3). Statistical analysis was performed using Student’s t test (two groups) or one-way ANOVA (multiple groups). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. CDC20 is associated with activation of the PI3K-AKT signaling pathway in prostate cancer cells A previous report showed that CDC20 could regulate PI3K-AKT pathway activity to promote cancer cell development.25To explore the molecular mechanisms underlying CDC20-mediated regulation of PCa progression, the activity of the PI3K-AKT signaling pathway was examined by western blot analysis. Silencing of CDC20 in DU145 and PC-3 cells resulted in a marked reduction in the phosphorylation levels of PI3K and AKT, as reflected by decreased p-PI3K/PI3K and p-AKT/AKT ratios. Conversely, CDC20 overexpression led to increased phosphorylation of PI3K and AKT in both cell lines (Figures 7A and 7B). These results indicate that CDC20 expression levels are positively associated with PI3K-AKT pathway activation in PCa cells. To further determine whether AKT signaling mediates the oncogenic effects of CDC20, we performed rescue experiments using a constitutively active AKT construct (myr-AKT) in CDC20-silenced cells. Expression of myr-AKT markedly restored the reduced phosphorylation of AKT induced by CDC20 knockdown and partially rescued the inhibitory effects on cell proliferation and migration (Figures 7C and 7D). These findings provide more specific evidence that AKT signaling contributes to CDC20-mediated tumor-promoting effects. Together, our results suggest that CDC20 promotes PCa cell proliferation and migration at least in part through the activation of the PI3K/AKT signaling pathway. CDC20 regulates the activity of PI3K-AKT pathway (A and B) Western blot analysis of CDC20, PI3K, p-PI3K, AKT, and p-AKT in DU145 and PC-3 cells. (C) CCK-8 assay evaluating proliferation in control and CDC20-knockdown DU145 cells with or without myr-AKT overexpression. (D) Transwell migration assay assessing cell migration under the indicated conditions (scale bars, 50 μm). ∗∗Data are presented as mean ± SD from three independent experiments (n = 3). Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. ∗∗p < 0.01, ∗∗∗p < 0.001. CDC20 interacts with c-MYC and modulates PI3K-AKT signaling in a c-MYC-dependent manner To further investigate the mechanisms of how CDC20 promotes PCa development, we performed an IP-mass spectrometry analysis to find out the potential interacting protein of CDC20. In the list, we found c-MYC, a well-established oncogenic transcription factor. To confirm the protein-protein interaction between CDC20 and c-MYC, we performed co-immunoprecipitation assays in DU145 and PC-3 cells, which confirmed that CDC20 physically associates with c-MYC (Figure 8A). To further examine the regulatory relationship between CDC20 and c-MYC, CDC20 was silenced in both cell lines. qRT-PCR analysis showed no significant change in c-MYC mRNA levels following CDC20 knockdown, whereas western blot analysis revealed a substantial reduction in c-MYC protein expression (Figure 8B), indicating that CDC20 may regulate c-MYC expression at a post-transcriptional level. This finding suggests that CDC20 may influence the stability or turnover of c-MYC protein, although the precise underlying mechanism remains to be further elucidated. Further evidence from our IHC results demonstrated a positive correlation between c-MYC and CDC20 expression (Figure 8C), supporting a potential functional association between these two proteins in PCa. CDC20 binds to and interacts with c-Myc to regulate the PI3K-AKT signaling pathway (A) Co-immunoprecipitation assay showing interaction between CDC20 and c-MYC. (B) Effect of CDC20 knockdown on c-MYC expression. (C) Representative IHC images of CDC20 and c-MYC in prostate cancer tissues (scale bars, 100 μm). (D) Western blot analysis of PI3K-AKT pathway after CDC20 overexpression with or without c-MYC knockdown. (E) CCK-8 assay evaluating proliferation under indicated conditions. (F) Transwell assay evaluating migration under indicated conditions (scale bars, 50 μm). ∗∗Data are presented as mean ± SD from three independent experiments (n = 3). Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. ∗∗p < 0.01, ∗∗∗p < 0.001. To assess whether c-MYC mediates the effects of CDC20 on PI3K-AKT signaling and cancer cell proliferation and migration, rescue experiments were performed by overexpressing CDC20 in DU145 cells with or without c-MYC knockdown. CDC20 overexpression markedly increased the phosphorylation levels of PI3K and AKT, while this effect was significantly attenuated when c-MYC was silenced (Figure 8D). Consistently, functional assays showed that CDC20 overexpression promoted cell proliferation and migration, whereas these effects were largely abolished upon c-MYC knockdown (Figures 8E and 8F). These findings indicate that the ability of CDC20 to activate PI3K-AKT signaling and promote malignant phenotypes is at least partially dependent on c-MYC. Together, our results support a model in which CDC20 regulates PI3K-AKT signaling in a c-MYC-dependent manner rather than acting solely through parallel pathways. Discussion In this study, we combined bioinformatics analyses with in vitro and in vivo experiments to systematically investigate the expression pattern, prognostic relevance, and potential molecular mechanisms of CDC20 in PCa. Our findings indicate that CDC20 is aberrantly upregulated in PCa and is independently associated with unfavorable clinical outcomes. Functional experiments further demonstrate that CDC20 contributes to malignant phenotypes of PCa cells, while mechanistic analyses suggest that CDC20 may modulate PI3K-AKT signaling in a c-MYC-dependent manner. Together, these results highlight CDC20 as a potential prognostic biomarker and a candidate therapeutic target in PCa. From a clinical perspective, elevated CDC20 expression may help identify patients with more aggressive disease and poorer prognosis, thereby providing potential value for risk stratification and clinical decision-making. Based on TCGA-PRAD data, CDC20 was identified from a panel of DEGs as an independent prognostic factor in PCa. Multivariate Cox regression analysis demonstrated that CDC20 expression remained significantly associated with DFS after adjustment for clinical variables. Consistent with previous reports in other malignancies, including colorectal26,27 and liver cancers,28,29 elevated CDC20 expression has been linked to aggressive tumor behavior and poor prognosis. In addition, the risk score constructed in this study effectively stratified patients with distinct survival outcomes, supporting the robustness of prognostic stratification. Notably, immune infiltration analysis revealed differences in immune cell composition between high- and low-risk groups, suggesting that CDC20-associated risk patterns may be accompanied by alterations in the tumor immune microenvironment. Interestingly, the high-risk group exhibited increased infiltration of CD8+ T cells and M1 macrophages, which are typically associated with antitumor immunity. This observation may appear counterintuitive, given the poorer prognosis of the high-risk group. However, in the context of PCa, the presence of immune cells does not necessarily reflect effective antitumor activity. Tumor-infiltrating CD8+ T cells may exhibit an exhausted phenotype characterized by impaired cytotoxic function and increased expression of immune checkpoint molecules, thereby limiting their antitumor efficacy.30 In addition, aggressive tumors may recruit immune cells through inflammatory signaling while simultaneously establishing an immunosuppressive microenvironment that inhibits their function.31 Furthermore, immune infiltration estimates based on bulk transcriptomic data may not fully capture the functional states or spatial distribution of immune cells. Therefore, the increased immune infiltration observed in the high-risk group may reflect a dysfunctional or suppressed immune context rather than an effective antitumor response. Although these observations warrant further validation, they provide preliminary insights into the potential interplay between CDC20-related molecular features and immune regulation in PCa. Functional assays demonstrated that CDC20 plays an important role in regulating PCa cell proliferation, migration, invasion, and cell cycle progression. Silencing CDC20 induced G2/M phase arrest and suppressed malignant phenotypes in DU145 and PC-3 cells, whereas CDC20 overexpression exerted opposite effects. It is noteworthy that both DU145 and PC-3 are androgen-independent PCa cell lines, and PC-3 in particular has been characterized as a neuroendocrine-like (NEPC-like) model. Therefore, the observed oncogenic effects of CDC20 may be especially relevant in advanced or CRPC contexts. Given its functional role in promoting tumor cell proliferation and progression, CDC20 may also represent a potential therapeutic target, and strategies aimed at modulating CDC20 activity or its downstream signaling pathways could provide new avenues for the treatment of advanced PCa. These findings are consistent with the established role of CDC20 as an activator of the anaphase-promoting complex/cyclosome (APC/C), which regulates cell cycle progression through the degradation of key substrates such as Cyclin B1 and securin.32,33 Given the importance of dysregulated cell cycle control in PCa progression, CDC20-mediated modulation of cell cycle dynamics may represent a critical mechanism contributing to tumor growth and aggressiveness. Moreover, the observed effects of CDC20 on cell migration and invasion suggest a potential role in PCa metastasis, which may be linked to ECM remodeling and related signaling pathways identified in enrichment analyses. In vivo xenograft experiments further supported the tumor-promoting role of CDC20, as CDC20 knockdown suppressed tumor growth, whereas CDC20 overexpression enhanced tumorigenicity. These in vivo findings are consistent with the in vitro data and underscore the biological relevance of CDC20 in PCa progression. Collectively, our study provides experimental evidence supporting the involvement of CDC20 in PCa development and progression, while also highlighting its potential as a therapeutic vulnerability. Together, these findings suggest that CDC20 may serve as both a prognostic biomarker and a potential target for therapeutic intervention, although further clinical validation is required. Mechanistically, our results suggest that CDC20 interacts with c-MYC and regulates its protein abundance at a post-transcriptional level. Knockdown of CDC20 reduced c-MYC protein levels without affecting its mRNA expression, indicating that CDC20 may influence c-MYC stability rather than transcription. Rescue experiments further demonstrated that restoration of c-MYC expression partially reversed the suppression of PI3K-AKT signaling induced by CDC20 silencing, supporting a c-MYC-dependent regulatory relationship. Similar post-translational regulatory roles of CDC20 have been reported in other tumor types, where CDC20 modulates the stability of oncogenic or tumor-suppressive proteins. Given the central role of PI3K-AKT signaling in PCa progression, metabolic reprogramming, and therapeutic resistance, CDC20-mediated regulation of this pathway via c-MYC may represent an additional layer of oncogenic control. Limitations of the study Several limitations of this study should be acknowledged. First, the bioinformatics analyses were based on publicly available TCGA data, and independent multi-center clinical cohorts are required to further validate the prognostic value of CDC20. Second, in vitro experiments were performed using androgen-independent PCa cell lines, and future studies incorporating androgen-dependent models will be necessary to clarify the role of CDC20 across different molecular subtypes of PCa. It should also be noted that the PC-3 cell line has been reported to exhibit neuroendocrine-like (NEPC-like) characteristics, representing a more aggressive and advanced subtype of PCa. Therefore, our findings may primarily reflect the biological behavior of androgen-independent or advanced-stage PCa, and caution should be exercised when extrapolating these results to other disease contexts. Third, although our data suggest post-transcriptional regulation of c-MYC by CDC20, the precise molecular mechanisms, including potential ubiquitin-mediated processes, remain to be elucidated. Finally, in vivo experiments were limited to subcutaneous xenograft models, and additional metastatic models, such as bone metastasis models, are needed to fully evaluate the role of CDC20 in PCa dissemination. Resource availability Lead contact Further information and requests for resources and reagents should be directed to and will be fulfilled or facilitated by the lead contact, Yizhou Wang (wangyizhou@foxmail.com). Materials availability This study did not generate new animals, cell lines, or unique reagents. Data and code availability •The transcriptomic and clinical data analyzed in this study are publicly available from the TCGA-PRAD project through the Genomic Data Commons (GDC) Data Portal (accession: TCGA-PRAD) and from the Gene Expression Omnibus (GEO) database (accessions: GSE21032 and GSE35988). Any processed data supporting the findings of this study are available from the corresponding author upon reasonable request. The transcriptomic and clinical data analyzed in this study are publicly available from the TCGA-PRAD project through the Genomic Data Commons (GDC) Data Portal (accession: TCGA-PRAD) and from the Gene Expression Omnibus (GEO) database (accessions: GSE21032 and GSE35988). Any processed data supporting the findings of this study are available from the corresponding author upon reasonable request. •This paper does not report original code. This paper does not report original code. •Any additional information required to reanalyze the data reported in this paper is available from the corresponding author upon reasonable request. Any additional information required to reanalyze the data reported in this paper is available from the corresponding author upon reasonable request. Acknowledgments KEGG pathway database is copyrighted by Kanehisa Laboratories, and we have formal permission from them to publish this material commercially under an Open Access license. This research was funded by the 23rd Batch of Science and Technology Development Plan of Suzhou City in 2023 (SLT2023008), the 28th Batch of Science and Technology Development Plan of Suzhou City in 2024 (applied basic research (medical and health) technological innovation) (SYW2024050), the Medical Research Project of Jiangsu Provincial Health Commission (Z2023051), and Changshu Municipal Health Commission Science and Technology Plan (CSWSQ202105). Author contributions Conceptualization, J.D., X.X., N.Z., and J.C.; methodology, Z.F., J.Z., and Y.W.; investigation, J.D., N.Z., J.C.,K.L., and C.W.; writing – original draft, J.D., X.X., N.Z., and J.C.; writing – review and editing, Z.F., J.Z., and Y.W.; funding acquisition, Y.W.; resources, X.X., W.Z., and J.Z.; supervision, J.Z. and Y.W. Declaration of interests The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. STAR★Methods Key resources table REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesanti-CDC20Cell Signaling TechnologyCat# 14866; RRID: AB_2715567anti-c-MYCCell Signaling TechnologyCat# 5605; RRID: AB_1903938anti-PI3KCell Signaling TechnologyCat# 4249; RRID: AB_2165248anti-phospho-PI3KCell Signaling TechnologyCat# 17366; RRID: AB_2895293anti-AKTCell Signaling TechnologyCat# 9272; RRID: AB_329827anti-phospho-AKTCell Signaling TechnologyCat# 4060; RRID: AB_2315049anti-GAPDHCell Signaling TechnologyCat# 2118; RRID: AB_561053Chemicals, peptides, and recombinant proteinsRPMI-1640Thermo Fisher11875093Fetal Bovine SerumGIBCO10099-141CPenicillin-StreptomycinGIBCO15140–122Lipofectamine 2000Yeasen40802ES01puromycinSolarbioP8230formaldehydeMACKLIN50-00-0RNase ABeyotimeST579DNase IRoche10104159001TRIzol reagentInvitrogen15596018CCK-8 reagentBeyotimeC0037Deposited dataTCGA Prostate Adenocarcinoma (TCGA-PRAD) datasetGenomic Data Commons (GDC)TCGA-PRADProstate cancer transcriptome datasetGene Expression Omnibus (GEO)GSE21032Metastatic prostate cancer transcriptome datasetGene Expression Omnibus (GEO)GSE35988Experimental models: Cell linesDU145ATCCHTB-81PC-3ATCCCRL-1435RM-1ATCCCRL-3310LNCaPATCCCRL-1740HEK293TFUHENG BIOLOGYFH0952RWPE-1ATCCCRL-3607Experimental models: Organisms/strainsBALB/c nude miceShanghai Yishang BiotechnologyN/ASoftware and algorithmsPrism 9.0https://www.graphpad.comGraphPadImageJhttps://imagej.nih.gov/ijversion: 1.42qlimma packagehttps://bioconductor.org/packages/release/bioc/html/limma.htmlversion 3.54.2Rhttps://www.r-project.orgR Foundation for Statistical Computing, Vienna, AustriaIllustratorAdobehttps://www.adobe.com Experimental model and study participant details Cell culture Human PCa cell lines (DU145, ATCC HTB-81; LNCaP, ATCC CRL-1740; PC-3, ATCC CRL-1435), murine PCa cells (RM-1, ATCC CRL-3310), normal prostate epithelial cells (RWPE-1, ATCC CRL-3607), and HEK293T cells (Fuheng Biology, Cat# FH0952) were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) at 37°C in a humidified atmosphere containing 5% CO2. Cells were passaged every 2–3 days at 70–80% confluency. All cell lines were obtained from authenticated commercial sources and maintained according to the suppliers’ recommendations. Human cell lines were authenticated by short tandem repeat (STR) profiling prior to experimentation. All cell lines were routinely tested and confirmed to be free of mycoplasma contamination before use. Mice Twenty-four male 6–8-week-old BALB/c nude mice were obtained from Shanghai Yishang Biotechnology Co., Ltd. All mice were housed in a specific pathogen-free (SPF) animal facility under controlled temperature and humidity conditions with a 12 h light/dark cycle and free access to food and water. The animal experimental protocol was reviewed and approved by the Animal Ethics Committee of Shanghai Yishang Biotech and was strictly conducted in accordance with the approved protocol (Approval No.: IACUC-2025-NI-066). All animal procedures were performed in accordance with institutional guidelines and relevant regulations for the care and use of laboratory animals. Because prostate cancer is a male-specific disease, only male mice were used in this study, and sex was not evaluated as an experimental variable. Clinical sample Adjacent benign prostate tissues and prostate cancer specimens from 70 prostate cancer patients (all male; median age, 71 years; range, 51–84 years) were collected and processed according to established histopathological protocols. All specimens were verified by pathological examination. Samples were classified into benign and prostate cancer groups based on pathological diagnosis. After collection, all tissues were stored at −80°C until further analysis. All procedures were approved by the Ethics Committee of Affiliated Changshu Hospital of Nantong University (Approval No. 2024-KY-ZX53), and written informed consent was obtained from each participant. This study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki. Because all participants were male patients with prostate cancer, sex was not analyzed as an independent biological variable in this study. Method details Data acquisition and screening of differentially expressed genes (DEGs) Transcriptomic data of PCa, including tumor and adjacent normal tissue samples with clinical and prognostic information, were downloaded from the TCGA database. Differentially expressed genes (DEGs) were identified using the R package limma,34 with preprocessing for normalization. DEGs were filtered using adjusted P-value <0.05 and |log2 (fold change)| > 1. Functional enrichment analyses DEGs were subjected to Gene Ontology (GO) and KEGG pathway enrichment analyses using the clusterProfiler35 R package, covering Biological Process (BP), Cellular Component (CC), Molecular Function (MF), and signaling pathways. Significantly enriched terms were identified based on P-value <0.05. Data visualization Heatmaps of DEG expression were generated with the pheatmap36 package. Bubble plots visualizing GO and KEGG results were created using clusterProfiler,37 where bubble size reflected gene counts and color reflected enrichment significance. Univariate and multivariate cox regression analyses A univariate Cox proportional hazards regression model was used to evaluate the association between the expression level of each gene and patients’ disease-free survival (DFS). The analysis was implemented using the coxph function in the “survival” package38 in R, with the following parameter settings: Dependent variable: Patient DFS status and DFS time (years). Independent variable: Gene expression values. Screening criteria: p < 0.05 and hazard ratio (HR) ≠ 1. Prognostic gene screening and visualization Forest plot generation: The “ggforest” function in the “survminer” package36 was used to generate forest plots, showing the HR and 95% confidence interval (CI) for each gene. Survival curve analysis: Patients were divided into high-expression groups and low-expression groups based on the median gene expression level. Kaplan-Meier curves were constructed using the “survfit” function, and visualization and Log rank tests were performed using the “ggsurvplot” function. On the basis of univariate analysis, clinical variables (age, pathological stage) were further included to construct a multivariate Cox proportional hazards model for screening independent prognostic genes. The analysis was performed using the “coxph” function in the “survival” package, combined with the “rms” package39 for model diagnosis and visualization. A bidirectional stepwise regression method was used for variable selection, and 8 significantly independent prognostic genes were finally retained. Construction and validation of the risk scoring model A risk scoring model (Riskscore) was constructed using a linear weighting method based on the expression of the 8 independent prognostic genes. The formula was as follows: where (Coef i) represented the regression coefficient of each gene from the multivariate Cox analysis, and (Gene i) represented the normalized gene expression value. Patients were divided into high-risk groups and low-risk groups based on the median Riskscore. Immune cell infiltration analysis CIBERSORT quantified the relative proportions of 22 immune cell types in TCGA-PCa samples. Based on RNA sequencing data (FPKM-normalized), the CIBERSORT algorithm was run using the “cibersort” package40 in R. Differential analysis. Differences between high- and low-risk groups were assessed by the Wilcoxon rank-sum test. Heatmaps and boxplots were visualized using ggplot2 and ggpubr. Cell culture Human PCa cell lines (DU145, LNCaP, PC-3), murine PCa line (RM-1), and normal prostate epithelial cells (RWPE-1) were cultured in RPMI-1640 with 10% FBS at 37°C, 5% CO2. Cells were passaged every 2–3 days at 70–80% confluency. Gene intervention Construction of cell lines with transient knockdown or overexpression of CDC20 in DU145 and PC-3 cells Knockdown experiment: CDC20-siRNA (si-CDC20) and negative control (si-NC) were transfected into cells using Lipofectamine 3000 reagent (Invitrogen). Overexpression experiment: Overexpression vectors (OE-CDC20 or OE-ANKRD1) and empty vectors (Vector) were transfected into cells. The overexpression vector pCDNA3.1-CDC20 (OE-CDC20, pcDNA3.1 vector: Invitrogen) and the empty vector were verified by sequencing. Transfection procedure: Cells were seeded into 6-well plates at a density of 2×105 cells/well 24 h before transfection. For siRNA transfection: Tube A: 50 μL Opti-MEM +5 μL Lipofectamine 3000 per well. Tube B: 50 μL Opti-MEM +2.5 μg siRNA (si-CDC20 or si-NC) per well. For plasmid transfection: Tube A: 50 μL Opti-MEM +5 μL Lipofectamine 3000 per well. Tube B: 50 μL Opti-MEM +2.5 μg plasmid (OE-CDC20 or Vector) per well. Tubes A and B were mixed and incubated at room temperature for 15 min. The complexes were then added to cells, and the medium was replaced with complete medium after 6 h. Cells were harvested 48 h after transfection for RNA or protein extraction. The siRNA sequences are shown as follows (5’→3′): Si-CDC20-1: sense: CCUGAAAUCCGAAAUGACUAU. Antisense: AGUCAUUUCGGAUUUCAGGCG. Si-CDC20: sense: GAUAACUUGGUCAAUGUGUGG. Antisense: ACACAUUGACCAAGUUAUCAU. Si-NC: sense: UUCUCCGAACGUGUCACGU. Antisense: ACGUGACACGUUCGGAGAA. Construction of cell lines with stable knockdown or overexpression of CDC20 Lentivirus Packaging and Infection: Lentiviral vectors: pLVX-CDC20-shRNA (sh-CDC20) and negative control (sh-NC) for knockdown; pLVX-CDC20 (OE-CDC20) and empty vector (Vector) for overexpression. Virus packaging: HEK293T cells were seeded into 10 cm dishes, and co-transfected with packaging plasmids (psPAX2, pMD2.G) and target plasmids (sh-CDC20, OE-CDC20) using Lipofectamine 3000. Viral supernatants were collected 48 h later and filtered through a 0.45 μm filter. Cell infection: cells were seeded into 6-well plates, and viral supernatants plus polybrene (8 μg/mL) were added. The medium was replaced with complete medium after 24 h, and cells were cultured for another 48 h. Knockdown cell lines: Puromycin (2 μg/mL) was used for selection for 2 weeks to obtain stable CDC20-knockdown cell lines (sh-CDC20). Overexpression cell lines: Hygromycin (200 μg/mL) was used for selection for 2 weeks to obtain stable CDC20-overexpression cell lines (OE-CDC20). Cells were seeded into 96-well plates using the limiting dilution method. Monoclonal colonies were selected, expanded, and their expression levels were verified. For AKT rescue experiments, a constitutively active AKT construct (myr-AKT) was transiently transfected into CDC20-silenced prostate cancer cells using Lipofectamine 3000 according to the manufacturer’s instructions. Cells transfected with empty vector served as controls. Quantitative real-time PCR (qRT-PCR) Total cellular RNA was extracted using TRIzol reagent (Cat 15596018, CNInvitrogen) according to the manufacturer’s instructions, and RNA concentration was measured using a NanoDrop spectrophotometer. A total of 1 μg RNA was reverse-transcribed into cDNA using a TaKaRa reverse transcription kit under the following conditions: 37°C for 15 min and 85°C for 5 s. A 20 μL reaction system was prepared, containing 10 μL SYBR Green Master Mix, 2 μL cDNA, and 0.8 μL each of forward and reverse primers, with three technical replicates set for each sample. The qRT-PCR program was as follows: pre-denaturation at 95°C for 30 s, followed by 40 cycles of denaturation at 95°C for 5 s and annealing/extension at 60°C for 30 s. A melting curve analysis was performed to verify the specificity of amplification. GAPDH was used as the internal reference gene, and the relative expression levels of target genes were calculated using the 2−ΔΔCt method. The sequences for the primers are listed below: CDC20-F: GCACAGTTCGCGTTCGAGA. CDC20-R: CTGGATTTGCCAGGAGTTCGG c-MYC-F: GTCACACCCTTCTCCCTTCG c-MYC-R: GCCGCTCCACATACAGTCC. GAPDH-F: GGAGCGAGATCCCTCCAAAAT. GAPDH-R: GGCTGTTGTCATACTTCTCATGG. Western blot analysis Total protein was extracted and quantified using the BCA protein assay kit. Proteins were separated by SDS-PAGE and transferred onto PVDF membranes, which were then blocked with 5% BSA. The membranes were incubated overnight at 4°C with primary antibodies: anti-CDC20 (1:1000, Cat.14866S, CST), anti-c-MYC (1:1000, Cat.5605T, CST), anti-PI3K (1:1000, Cat.4249T, CST), anti-phospho-PI3K (p-PI3K, 1:1000, Cat.17366T, CST), anti-AKT (1:1000, Cat.927S, CST), anti-phospho-AKT (p-AKT, 1:1000, Cat.4060T, CST), and anti-GAPDH (1:5000, Cat.2118T, CST). After washing, the membranes were incubated with secondary antibodies at room temperature for 1 h. Protein bands were visualized using ECL chemiluminescence, and the gray values of bands were quantified using ImageJ software. GAPDH was used as the internal reference to calculate the relative protein expression levels. CCK-8 assay Cells were seeded into 96-well plates at a density of 3000 cells/well and cultured for 24 h, after which the medium was replaced with medium containing different treatment factors. Ten microliters of CCK-8 reagent (Cat. C0037, Beyotime) was added to each well, and cells were incubated at 37°C for 2 h. The absorbance at 450 nm was measured using a microplate reader. Wells without cells were used for background correction. Cell viability was calculated using the formula: Cell viability (%) = (OD value of treatment group/OD value of control group) × 100%. Colony formation assay Cells were digested, counted, and seeded into 6 cm culture dishes at a density of 500 cells/dish. The dishes were gently shaken to ensure uniform cell distribution. Cells were cultured at 37°C for 7–14 days. After colonies were formed (>50 cells per colony), cells were washed with PBS, fixed with 4% paraformaldehyde for 15 min, and stained with crystal violet for 20 min. Colonies were photographed and counted (colonies >0.5 mm were considered valid). Transwell assay Migration Assay: A total of 200 μL cell suspension (containing 5×104 cells in serum-free medium) was added to the upper chamber of a Transwell insert, and 600 μL medium containing 20% FBS was added to the lower chamber. After incubation at 37°C for 24 h, non-migrated cells in the upper chamber were wiped off with a cotton swab. Migrated cells in the lower chamber were fixed with 4% paraformaldehyde and stained with crystal violet. Cells were photographed under a microscope (×100), and the number of migrated cells was counted in 5 randomly selected fields. Invasion Assay: The upper chamber was pre-coated with Matrigel matrix (50 μg/well) before seeding cells. The remaining steps were the same as those for the migration assay. Wound healing assay Cells were seeded into 6-well plates and cultured until reaching 90% confluency. A 200 μL pipette tip was used to scratch the cell monolayer vertically. Cells were washed 3 times with PBS to remove detached cells, and the medium was replaced with serum-free medium. Images were captured at 0 h, 24 h, and 48 h under a microscope (×40). The wound healing area was measured using ImageJ software. Cell cycle analysis A total of 1×106 cells were collected, washed with PBS, and fixed with 70% ethanol at 4°C overnight. After centrifugation to remove ethanol, cells were resuspended in PBS, treated with RNase (50 μg/mL) at 37°C for 30 min, and then stained with propidium iodide (PI, 50 μg/mL, containing 0.1% Triton X-100) at room temperature in the dark for 30 min. Cell cycle distribution was detected using a flow cytometer (BD FACSCanto II), and the proportions of cells in G0/G1, S, and G2/M phases were analyzed using ModFit LT software. Co-immunoprecipitation (CO-IP) assay Total cellular protein was extracted using RIPA lysis buffer containing protease inhibitors. A total of 500 μg protein was incubated with 2 μg target antibody at 4°C with rotation overnight. Then, 30 μL Protein A/G agarose beads were added, and the mixture was incubated at 4°C with rotation for 2 h. The beads were washed 5 times with PBS, and 2×SDS loading buffer was added. The mixture was boiled at 100°C for 5 min, centrifuged, and the supernatant was subjected to Western blot analysis using anti-c-MYC and anti-CDC20 antibodies. Animal model construction The animal experimental protocol was reviewed and approved by the Animal Ethics Committee of Shanghai Yishang Biotech and was strictly conducted in accordance with the approved protocol (Approval No.: IACUC-2025-NI-066). Twenty-four male 6-8-week-old BALB/c nude mice were obtained from Shanghai Yishang Biotechnology. All mice were randomly assigned to four groups: sh-NC, sh-CDC20, Vector, and OE-CDC20. Each mouse received a subcutaneous injection of 1×106 stably transfected DU145 in 100 μL PBS into the right flank. Tumor length (L) and width (W) were measured every 3 days with a vernier caliper, and tumor volume was calculated as V = 0.5 × L × W2. Body weight was recorded weekly. After 4 weeks, mice were euthanized, tumors were excised, weighed, and processed: part of the tissue was fixed in 4% paraformaldehyde for histological analysis, and the remainder was stored at −80°C. All procedures were performed in accordance with relevant institutional guidelines and regulations and included measures to minimize animal suffering. Immunohistochemistry (IHC) Adjacent benign and prostate cancer tissues were processed according to established protocols.41 IHC was performed using the streptavidin-biotin-peroxidase method as previously described.42,43 Briefly, protein staining was conducted after deparaffinization and citrate buffer-mediated antigen retrieval (pH 6), with diaminobenzidine as the chromogen. Negative controls were generated by omitting the primary antibody or substituting it with an irrelevant antibody. Staining was independently evaluated by two observers, including a pathologist, and consensus scores were assigned. Protein expression was semi-quantitatively assessed by combining staining intensity (0–3) and the proportion of positive cells (0–3), and categorized as negative (0), weak (1–2), moderate (3–4), or strong (5–6).44 Quantification and statistical analysis Statistical analyses were performed using R (v4.0.0) and GraphPad Prism (v9.0.0). For TCGA-PRAD data, DEG screening, enrichment analyses, prognostic gene identification, and immune cell infiltration comparisons were conducted using the statistical methods described above. Experimental data are presented as mean ± SD from at least three independent biological replicates. Comparisons between two groups were performed using an unpaired two-tailed Student’s t test, whereas comparisons among multiple groups were analyzed using one-way ANOVA followed by Tukey’s post hoc test. Kaplan-Meier survival analyses were evaluated using the log rank test. Statistical significance was defined as ∗p < 0.05, ∗∗p < 0.01, and ∗p < 0.001. Footnotes Supplemental information can be found online at https://doi.org/10.1016/j.isci.2026.116409. Contributor Information Jing Zhai, Email: drzjurology@163.com. Yizhou Wang, Email: wangyizhou@foxmail.com. Supplemental information Document S1. Figure S1 Document S2. Data S1 and S2 References Associated Data Supplementary Materials Document S1. Figure S1 Document S2. Data S1 and S2 Data Availability Statement •The transcriptomic and clinical data analyzed in this study are publicly available from the TCGA-PRAD project through the Genomic Data Commons (GDC) Data Portal (accession: TCGA-PRAD) and from the Gene Expression Omnibus (GEO) database (accessions: GSE21032 and GSE35988). Any processed data supporting the findings of this study are available from the corresponding author upon reasonable request. The transcriptomic and clinical data analyzed in this study are publicly available from the TCGA-PRAD project through the Genomic Data Commons (GDC) Data Portal (accession: TCGA-PRAD) and from the Gene Expression Omnibus (GEO) database (accessions: GSE21032 and GSE35988). Any processed data supporting the findings of this study are available from the corresponding author upon reasonable request. •This paper does not report original code. This paper does not report original code. •Any additional information required to reanalyze the data reported in this paper is available from the corresponding author upon reasonable request. Any additional information required to reanalyze the data reported in this paper is available from the corresponding author upon reasonable request.